HJB647 high dose Clinical Trials (2026): 1 Studies for Heart Failure With Reduced Ejection Fraction
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 HJB647 high dose clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Heart Failure With Reduced Ejection Fraction) and 12 total planned enrollment. 1 HJB647 high dose clinical trial is actively recruiting at 3 U.S. sites across 1 state. Most recent activity: NCT07465653 (Sep 2026).
Where to Participate: All HJB647 high dose Trial Sites in the U.S. (3 sites across 1 state)
Every actively recruiting HJB647 high dosetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | Synergy Healthcare | Bradenton34208 | NCT07465653 | Map |
| FL | Nature Coast Clinical Research LLC | Inverness34452 | NCT07465653 | Map |
| FL | Jacksonville Center for Clinical | Jacksonville32216 | NCT07465653 | Map |
HJB647 high dose clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting HJB647 high dose clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | P1 | Heart Failure With Reduced Ejection Fraction | 12 | Mar 2026 |
All HJB647 high dose trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07465653 | A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction | P1 | recruiting | 12 | Novartis Pharmaceuticals | Mar 2026 |
HJB647 high dose clinical trials: frequently asked questions
- How many HJB647 high dose clinical trials are there?
- 1 HJB647 high dose clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are HJB647 high dose clinical trials recruiting in 2026?
- Yes — 1 HJB647 high dose trial is actively recruiting in 2026, with 3 U.S. sites across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is HJB647 high dose being studied for?
- HJB647 high dose is being studied for Heart Failure With Reduced Ejection Fraction. The trials are grouped by indication on this page.
- What phase is HJB647 high dose in?
- HJB647 high dose clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors HJB647 high dose clinical trials?
- The lead sponsor across the most HJB647 high dose trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming HJB647 high doseas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: